{"schema_version":"secwatch.filing_event.v1","accession":"0001411690-24-000004","form_type":"8-K","ticker":"BNGO","cik":"0001411690","company_name":"Bionano Genomics, Inc.","filed_at":"2024-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.108498+00:00","generated_at":"2026-06-05T03:40:25.413353+00:00","sec_items":["2.02","2.05","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Bionano Genomics reports Q4 revenue $10.7M (+30% YoY), announces 34-39% workforce reduction","bullets":["Q4 2023 revenue $10.7M, FY 2023 revenue $36.1M, both up 30% YoY.","GAAP gross margin Q4 23%, FY 26% (up from 21% in 2022).","Plans to cut 110-125 employees (34-39% of workforce) and phase out testing services generating 19.4% of FY 2023 revenue.","Restructuring expected to yield $35-40M annual operating expense savings starting H2 2024.","No specific 2024 revenue guidance provided; cash and securities $102.3M at year-end."],"urls":{"canonical":"https://secwatch.observer/filing/0001411690-24-000004","json":"https://secwatch.observer/filing/0001411690-24-000004.json","markdown":"https://secwatch.observer/filing/0001411690-24-000004.md","text":"https://secwatch.observer/filing/0001411690-24-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1411690/000141169024000004/0001411690-24-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1411690/000141169024000004/bngo-20240301.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T03:40:25.413353+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f9f7311476bcb1df64df7e4748fc120efbc7f360","claim":"Bionano Genomics, Inc. reported the fourth quarter and full year ended December 31, 2023 results: revenue $10.7 million.","evidence_excerpt":"Bionano Reports Fourth Quarter and Full-Year 2023 Results and Provides Revenue Outlook for 2024 • Q4 2023 revenue was $10.7 million , which represents a 30% increase over Q4 2022 • FY 2023 revenue was $36.1 million , which represents a 30% increase over FY 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1411690/000141169024000004/0001411690-24-000004-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2023"},{"label":"Revenue","value":"$10.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"e3ac1c2c0f6b11672fb3d18faeaaa12da1a1ba44","claim":"Bionano Genomics, Inc. announced a restructuring affecting global operations (approximately 110 to 125 employees).","evidence_excerpt":"On March 1, 2024, the Company committed to a corporate reorganization plan (the “Plan”), including a reduction in force (the “Reduction”) intended to decrease expenses and maintain a streamlined organization to support key programs that are expected to drive long-term growth.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1411690/000141169024000004/0001411690-24-000004-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Affected area","value":"global operations"},{"label":"Headcount","value":"approximately 110 to 125 employees"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}